Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
garsorasib + benmelstobart + anlotinib
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of garsorasib (also known as goselasib or D-1553), benmelstobart (TQB2450), and anlotinib (AL3818). It is currently being investigated as a first-line treatment for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC). Garsorasib is a potent and selective small-molecule inhibitor of the KRAS G12C mutation, which locks the protein in its inactive GDP-bound state to inhibit downstream oncogenic signaling. Benmelstobart is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), designed to block the PD-1/PD-L1 pathway and restore T-cell-mediated anti-tumor immunity. Anlotinib is a multi-targeted tyrosine kinase inhibitor that primarily inhibits VEGFR1/2/3, FGFR1/2/3/4, PDGFR alpha/beta, and c-Kit, thereby suppressing tumor angiogenesis and growth. The triple combination aims to provide a synergistic therapeutic effect by simultaneously targeting the driver mutation, the immune microenvironment, and tumor vascularization.
- Other names
- Goselasib + Benmelstobart + Anlotinib
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)CD274 (Programmed cell death protein 1 ligand 1)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on garsorasib + benmelstobart + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on garsorasib + benmelstobart + anlotinib.